Visara expands ophthalmology pipeline with exclusive license for investigational nerve growth factor therapy
NBP•Visara secured exclusive worldwide rights, excluding Greater China, to develop and commercialize HT006.2.2 as VIS-102 for neurotrophic keratitis. Wuhan Hiteck will receive an upfront payment, milestone payments and tiered royalties on net sales.
1. License agreement
Visara entered an exclusive license agreement with Wuhan Hiteck for VIS-102, an investigational nerve growth factor therapy for neurotrophic keratitis. The agreement covers worldwide development and commercialization rights except in Greater China, with Hiteck due upfront and milestone payments and tiered royalties on net sales.
